Sign in
Taking people in United StatesNo phase

Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA

Key facts

Who runs it
Artivion Inc.
Where
Ann Arbor, Atlanta, Aurora, Austin, Baltimore, Birmingham, Chicago, Cleveland, Gainesville, Houston, Los Angeles, Milwaukee, New York, Philadelphia, Pittsburgh, Plano, Seattle, The Bronx, and Washington D.C., United StatesSee the 22 sitesAlso in 2 other countries, 4 sites
Trial code
Status
Recruiting
People taking part
132 people, planned
Started
4 Nov 2025
Expected to end
Jul 2032
Type of study
Interventional
Treatments tested
  • Arcevo™ LSA Hybrid Stent Graft System
Record updated
15 October 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 35 criteriaShow less

Other criteria

  • General Inclusion Criteria
  • ≥18 years of age or ≤80 years of age (male or female) at time of surgery
  • Patient has one of the following indications for open surgery based on computed tomography angiography (CTA) completed within 90 days of informed consent:; Acute, subacute, or chronic dissection that involves the aortic arch and the descending thoracic aorta, with or without involvement of the ascending aorta; Aneurysm that involves the aortic arch and the descending thoracic aorta, with or without involvement of the ascending aorta
  • Patient, or patient's legally authorized representative (LAR; in the secondary arm only), provides written informed consent prior to any study procedures
  • Patient's surgery occurs within 90 days of informed consent; Anatomical Inclusion Criteria
  • Aortic diameter at the intended Arcevo™ LSA anastomosis site is ≥ 21 mm
  • For Aneurysm with distal sealing (i.e., single stage procedure), aortic diameter at the intended distal sealing zone is between 20-36 mm
  • For Dissection with distal sealing, aortic diameter at the intended distal sealing zone is between 22-40 mm
  • LSA branch does not require additional stenting further into the LSA (beyond the Arcevo™ LSA)
  • The intended LSA sealing zone has a diameter between 8.5 mm and 14.0 mm with a length of at least 10 mm
  • Absence of dissection, aneurysm, or stenosis in the intended LSA sealing zone
  • The intended LSA branch position does not interrupt flow to any branch vessel (e.g., left vertebral artery)
  • Patient does not have computed tomography (CT) evidence of extreme arch or LSA angulation precluding safe passage of the Arcevo™ LSA and delivery system
  • LSA take-off angle between 15° and 90°
  • For patients requiring planned extension, there is a ≥ 2 cm distal seal zone for the TEVAR device without a severely angulated descending aorta
  • For patients requiring planned extension, patient has suitable iliac artery anatomy for safe passage of the TEVAR delivery system; General Exclusion Criteria
  • Patient is pregnant, or planning to become pregnant during the course of the study; individuals of child-bearing potential must agree to use acceptable methods of contraception during the study
  • Patient has another medical condition (aside from the arch disease) that, in the opinion of the investigator, reduces the patient's life expectancy to < 2 years
  • Patient has an existing aortic stent graft device in the descending aorta that would interact with Arcevo™ LSA
  • Patient has a medical, social, or psychological problem that, in the opinion of the investigator, could impede the patient's ability to return for follow-up
  • Patient is unwilling or unable to comply with the follow-up schedule
  • Patient is institutionalized due to administrative or judicial order
  • Patient is unwilling to accept blood transfusion or blood product
  • Patient is currently participating in another interventional clinical study which includes treatment with another investigational product (e.g., device, pharmaceutical or biologic); Medical Exclusion Criteria
  • Patient is unfit for open surgical repair involving circulatory arrest
  • Patient is in extreme hemodynamic compromise requiring cardiopulmonary resuscitation (CPR) or substantial inotropic support prior to surgery
  • Patient has an active systemic infection
  • Patient has endocarditis or active infection of the aorta
  • Patient has a freely ruptured aorta
  • Patient has a history of a bleeding disorder (e.g., hemophilia)
  • Patient has current end-stage renal disease (e.g., GFR <30 mL/min)
  • Patient has a known allergy to Arcevo™ LSA components and TEVAR device components (if required) (nitinol, polyester, platinum-iridium, or polyethylene)
  • Patient has uncontrollable anaphylaxis to iodinated contrast or other inability to obtain CT angiograms during follow-up
  • Patient has acute coronary malperfusion
  • Patient has symptomatic visceral malperfusion

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

Also in 2 other countries, 4 sites

  • University of MichiganAnn Arbor, United StatesContact: China GreenTaking people
  • Emory University School of MedicineAtlanta, United StatesContact: Kim BaioTaking people
  • University of Colorado HospitalAurora, United StatesContact: Tien NgoTaking people
  • University of Texas AustinAustin, United StatesContact: Andrea Stapper, MBATaking people
  • Johns Hopkins HospitalBaltimore, United StatesContact: Lisa FornaresioTaking people
  • University of AlabamaBirmingham, United StatesContact: Marissa WaiteTaking people
  • Northwestern University Feinberg School of MedicineChicago, United StatesContact: Andrea SilvermanTaking people
  • Cleveland Clinic FoundationCleveland, United StatesContact: Laurie Moennich, PhDTaking people
  • University of Florida - ShandsGainesville, United StatesContact: Jessica CobbTaking people
  • University of Texas, McGovern Medical CenterHouston, United StatesContact: Mariano MontemayorTaking people
  • University of Southern CaliforniaLos Angeles, United StatesContact: Stephanie VarelaTaking people
  • Medical College of WisconsinMilwaukee, United StatesContact: Kelly PotznerTaking people
  • Columbia University Irving Medical Center/New York Presbyterian HospitalNew York, United StatesContact: Amanda AlonsoTaking people
  • Cornell Medical College (Presbyterian Weill)New York, United StatesContact: Marshagay RodriguezTaking people
  • Northwell HealthNew York, United StatesContact: Michelle VovshaTaking people
  • Jefferson HealthPhiladelphia, United StatesContact: Meckenzie BehrTaking people
  • Allegheny General HospitalPittsburgh, United StatesContact: Tracy SpirkTaking people
  • University of Pittsburgh Medical CenterPittsburgh, United StatesContact: Kristin KonopkaTaking people
  • Baylor Scott & WhitePlano, United StatesContact: Walter CerqueiraTaking people
  • University of Washington - Harborview Medical CenterSeattle, United StatesContact: Alex RuizTaking people
  • Montefiore Medical CenterThe Bronx, United StatesContact: Magdalena Mamczur-MadryTaking people
  • MedStar Washington HealthWashington D.C., United StatesContact: Katharine MahoneyTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if the Arcevo LSA stent graft can safely and effectively treat patients that have an acute or chronic aortic dissection and/or aneurysm that involves the aortic arch and the descending thoracic aorta, with or without the involvement of the ascending aorta.

The group in the trial

  • Arcevo LSATreatment being tested

    The Primary study arm will consist of patients with an aortic aneurysm or chronic aortic dissection (n=117). The Secondary study arm will include patients with acute or subacute aortic dissections (n=15).

    Treatment: Arcevo™ LSA Hybrid Stent Graft System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multi-center Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA in the Open Repair of Aortic Arch Aneurysms and Dissections
Fit questions
Built from NCT07089576, who can take part
Record updated
15 October 2026